Antares gets $105M from Novartis for new cancer drugs

Adam Friedman, CEO of the Scorpion Therapeutics spinout, said the deal helps both companies accelerate research "faster than either of us could alone." ...

Antares Therapeutics signs potential $1.9 billion cancer drug deal with Novartis

June 24 (Reuters) - Antares Therapeutics said on Wednesday it entered a collaboration with Novartis that could be worth up to ...
Hosted on MSN

Novartis, Antares partner to pursue undruggable cancer targets in $1.9 billion deal

Antares Therapeutics on Wednesday entered into a strategic collaboration with Novartis AG NVS aimed at discovering, developing, and commercializing small-molecule therapies targeting historically ...
GlobalData on MSN

Novartis targets undruggable cancers with $1.9bn Antares Therapeutics deal

Antares’ lead precision oncology programme is expected to enter the clinic in 2026.
Nasdaq

Antares Closes $1.2 Billion Private Credit Continuation Vehicle Led by Ares Management

CHICAGO & NEW YORK--(BUSINESS WIRE)-- Antares Capital and Ares Management Corporation (“Ares”) (NYSE: ARES) today announced the closing of Antares’ first continuation vehicle with over $1.2 billion in ...
Wall Street Journal

Antares Closes $1.2 Billion Credit Secondary Deal to Cash Out Fund Investors

Antares Capital has brought in Ares Management to help cash out investors in two older funds, forming one of several large private-credit continuation funds to hit the market in recent months. Chicago ...